Ionis Pharmaceuticals Selects Kastle Therapeutics as its New Commercial Partner for Kynamro®
By Natasha Berry, Jawala Prasad & Heather Cartwright
Pharma Deals Review: Vol 2016 Issue 5 (Table of Contents)
Published: 20 May-2016
DOI: 10.3833/pdr.v2016.i5.2159 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
After disappointing sales of Kynamro® (mipomersen) prompted Ionis Pharmaceuticals to terminate its licensing agreement with Sanofi Genzyme in January 2016, the antisense developer has now sold global development and commercialisation rights to the orphan drug to start-up Kastle Therapeutics in a deal worth up to US$95 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS